Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA.
Center for Neurointestinal Health, Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Int J Eat Disord. 2023 Mar;56(3):616-627. doi: 10.1002/eat.23874. Epub 2022 Dec 22.
Avoidant/restrictive food intake disorder (ARFID) symptoms are common (up to 40%) among adults with disorders of gut-brain interaction (DGBI), but treatments for this population (DGBI + ARFID) have yet to be evaluated. We aimed to identify initial feasibility, acceptability, and clinical effects of an exposure-based cognitive-behavioral treatment (CBT) for adults with DGBI + ARFID.
Patients (N = 14) received CBT as part of routine care in an outpatient gastroenterology clinic. A two-part investigation of the CBT included a retrospective evaluation of patients who were offered a flexible (8-10) session length and an observational prospective study of patients who were offered eight sessions. Feasibility benchmarks were ≥75% completion of sessions, quantitative measures (for treatment completers), and qualitative interviews. Acceptability was assessed with a benchmark of ≥70% patients reporting a posttreatment satisfaction scores ≥3 on 1-4 scale and with posttreatment qualitative interviews. Mixed model analysis explored signals of improvement in clinical outcomes.
All feasibility and acceptability benchmarks were achieved (and qualitative feedback revealed high satisfaction with the treatment and outcomes). There were improvements in clinical outcomes across treatment (all p's < .0001) with large effects for ARFID fear (-52%; Hedge's g = 1.5; 95% CI = 0.6, 2.5) and gastrointestinal-specific anxiety (-42%; Hedge's g = 1.0; 95% CI = 0.5, 16). Among those who needed to gain weight (n = 10), 94%-103% of expected weight gain goals were achieved.
Initial development and testing of a brief 8-session CBT protocol for DGBI + ARFID showed high feasibility, acceptability, and promising clinical improvements. Findings will inform an NIH Stage 1B randomized control trial.
While cognitive-behavioral treatments (CBTs) for ARFID have been created in outpatient feeding and eating disorder clinics, they have yet to be developed and refined for other clinic settings or populations. In line with the recommendations for behavioral treatment development, we conducted a two-part investigation of an exposure-based CBT for a patient population with high rates of ARFID-adults with disorders of gut-brain interaction (also known as functional gastrointestinal disorders). We found patients had high satisfaction with treatment and there were promising improvements for both gastrointestinal and ARFID outcomes. The refined treatment includes eight sessions delivered by a behavioral health care provider and the findings reported in this article will be studied next in an NIH Stage 1B randomized controlled trial.
在患有肠-脑互动障碍(DGBI)的成年人中,回避/限制型食物摄入障碍(ARFID)的症状很常见(高达 40%),但针对这一人群(DGBI + ARFID)的治疗方法尚未得到评估。我们旨在确定基于暴露的认知行为治疗(CBT)对患有 DGBI + ARFID 的成年人的初步可行性、可接受性和临床效果。
患者(N=14)在门诊胃肠病诊所接受 CBT 作为常规护理的一部分。对 CBT 的两部分调查包括对接受灵活(8-10)次疗程的患者进行回顾性评估和对接受 8 次疗程的患者进行观察性前瞻性研究。可行性基准是完成疗程的比例≥75%、定量测量(针对治疗完成者)和定性访谈。可接受性通过以下基准来评估:≥70%的患者报告治疗后满意度评分≥1-4 分中的 3 分,以及治疗后定性访谈。混合模型分析探讨了临床结果改善的信号。
所有可行性和可接受性基准均达到(定性反馈显示对治疗和结果非常满意)。在治疗过程中,临床结果均有所改善(所有 p 值均<.0001),对 ARFID 恐惧(-52%;Hedge's g=1.5;95%CI=0.6, 2.5)和胃肠道特异性焦虑(-42%;Hedge's g=1.0;95%CI=0.5, 16)的影响较大。在需要增重的患者中(n=10),达到预期增重目标的 94%-103%。
DGBI + ARFID 的简短 8 次 CBT 方案的初步开发和测试显示出较高的可行性、可接受性和有希望的临床改善。研究结果将为 NIH 阶段 1B 随机对照试验提供信息。
虽然 ARFID 的认知行为治疗(CBT)已在门诊喂养和进食障碍诊所中创建,但尚未针对其他诊所环境或人群进行开发和完善。根据行为治疗开发的建议,我们对基于暴露的 CBT 进行了两部分调查,该 CBT 针对的是 ARFID 发病率高的患者人群——患有肠-脑互动障碍(也称为功能性胃肠道障碍)的成年人。我们发现患者对治疗非常满意,胃肠道和 ARFID 结果均有明显改善。经过改良的治疗包括由行为健康护理提供者提供的 8 次疗程,本研究报告的结果将在接下来的 NIH 阶段 1B 随机对照试验中进行研究。